Initial Investigation and Management of Elevated Liver Function Tests (LFTs)

Initial Assessment

• The American College of Radiology recommends a comprehensive laboratory workup, including complete blood count, urinalysis, serum electrolytes, blood urea nitrogen, serum creatinine, fasting blood glucose, lipid profile, and thyroid-stimulating hormone, for patients with elevated LFTs 1
• Measuring both aminotransferases (ALT, AST) and cholestatic markers (ALP, GGT, bilirubin) is necessary to determine the pattern of liver injury, according to the American College of Radiology 1
• Checking serum creatine kinase (CK) can help rule out muscle injury as a cause of elevated AST, as suggested by the Journal of Autoimmunity 2

Pattern-Based Investigation

• Common causes of hepatocellular pattern (elevated ALT/AST) include nonalcoholic fatty liver disease (NAFLD), alcohol-induced liver disease, viral hepatitis, and drug-induced liver injury, according to the American College of Radiology 1
• The American College of Radiology recommends checking viral hepatitis markers, such as anti-HAV IgM, HBsAg, anti-HBc IgM, and anti-HCV, in patients with hepatocellular pattern 2
• Evaluating alcohol consumption history and medication/supplement use is crucial in patients with hepatocellular pattern, as suggested by the Journal of Autoimmunity 2

Severity Classification

• The American College of Radiology classifies aminotransferase elevations as mild (<5× upper limit of normal), moderate (5-10× ULN), or severe (>10× ULN) 1
• Life-threatening elevations are defined as >20× ULN and require immediate intervention, according to Alimentary Pharmacology and Therapeutics 3

Management Based on Severity

• For mild elevations (<5× ULN), monitoring liver enzymes weekly until normalization is recommended, as suggested by Alimentary Pharmacology and Therapeutics 3
• For moderate to severe elevations (5-20× ULN), monitoring liver enzymes every 2-3 days until stable or improving is necessary, according to Alimentary Pharmacology and Therapeutics 3
• Immediate hospitalization for intensive monitoring is required for life-threatening elevations (>20× ULN), as recommended by Alimentary Pharmacology and Therapeutics 3

Special Considerations

• Obtaining a detailed medication history, including prescription drugs, over-the-counter medications, and supplements, is essential in patients with suspected drug-induced liver injury, according to the Journal of Autoimmunity 2
• For patients on immune checkpoint inhibitors with Grade ≥2 hepatitis (ALT >3× ULN), holding treatment and evaluating for other causes is recommended, as suggested by the Journal of Clinical Oncology 4

Follow-up Recommendations

• Repeat testing frequency should be based on the severity of elevation and clinical context, according to Alimentary Pharmacology and Therapeutics 3
• Referral to hepatology is considered for persistent unexplained elevations, evidence of advanced fibrosis, or ALT >5× ULN, as recommended by the American College of Radiology 1

Laboratory Workup for Elevated Liver Function Tests

Initial Evaluation

• The British Society of Gastroenterology emphasizes that imaging helps exclude biliary obstruction or neoplasm and should be obtained early in the evaluation, with abdominal ultrasound recommended as part of the initial workup to evaluate liver parenchyma, assess for steatosis, exclude masses, and evaluate the biliary system 5

Severity-Based Monitoring and Referral

• The British Society of Gastroenterology suggests 3-6 months of observation with repeat testing before proceeding to liver biopsy, if initial workup is unrevealing and LFTs remain mildly elevated, during which time potential hepatotoxins should be eliminated and metabolic risk factors addressed 5

Evaluation and Management of Elevated Liver Function Tests

Initial Laboratory Testing

• The European Association for the Study of the Liver recommends immediately obtaining viral hepatitis serologies, autoimmune markers, iron studies, and alpha-1-antitrypsin levels to exclude alternative or additional causes of liver injury 6, 7
• The American Association for the Study of Liver Diseases suggests that viral hepatitis screening should include hepatitis B surface antigen, hepatitis B core antibody IgM, hepatitis C antibody, and anti-HAV IgM if acute presentation 6, 7
• Autoimmune markers such as antinuclear antibody, anti-smooth muscle antibody, and anti-mitochondrial antibody should be obtained to exclude autoimmune hepatitis 6, 7
• Metabolic screening including transferrin and transferrin saturation, alpha-1-antitrypsin level, and ceruloplasmin should be performed 6, 7

Assessment of Liver Synthetic Function

• The American Association for the Study of Liver Diseases recommends obtaining serum albumin, prothrombin time/INR, total and direct bilirubin, and complete blood count with platelets to evaluate liver synthetic function 6, 7

Imaging Studies

• Abdominal ultrasound should be performed to assess liver parenchyma for steatosis, exclude biliary obstruction, detect focal liver lesions, and evaluate for signs of portal hypertension 6, 7

Non-Invasive Fibrosis Assessment

• The European Association for the Study of the Liver suggests calculating the FIB-4 score using age, ALT, AST, and platelet count to assess fibrosis risk 7
• Transient elastography (FibroScan) may be considered to assess liver fibrosis 6, 7

Common Pitfalls to Avoid

• Approximately 20% of patients with abnormal liver function tests have a co-existing etiology beyond the obvious cause, highlighting the importance of proper evaluation 6, 7